Matthew K. Fust, Director at Crinetics Pharmaceuticals, Inc. (CRNX), sold 5,700 shares at $20.96 ($119K) on 2022-07-13, disclosed to the SEC on 2022-07-15.
Open-market sale of $119k CRNX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| CRNX | SELL | 2024-03-22 | $2.1M | — | Filing → |
| RARE | SELL | 2024-03-11 | $859K | — | Filing → |
| ATRA | SELL | 2021-11-05 | $260K | — | Filing → |